Efficacy of inhaled Desmopressin in pregnant women with idiopathic oligohydramnios - a randomized controlled trial

What Was Tested

The paper reports a study of Vasopressin and Desmopressin, published as a randomized controlled trial.

The aim of this study was to investigate the therapeutic effect of inhaled Desmopressin (DDAVP) in pregnant women with idiopathic oligohydramnios.

Why It Was Studied

This randomized, double-blind clinical trial involved 44 pregnant women at 28-37 weeks of gestation with idiopathic oligohydramnios admitted in 2 academic hospitals in Mashhad, Iran, from 2018 to 2019.

The control group received intravenous maintenance fluid.

Who Took Part

According to the abstract, 44 women were involved.

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vasopressin study, the assignments were hidden from both participants and investigators until the end.

The hematocrit, electrolytes, blood pressure and urine-specific gravity were evaluated at baseline and 3, 8, and 24 hours later.

Amniotic fluid index (AFI) was measured using ultrasound at baseline, 24 and 48 hours later.

What Was Measured

Topics PubMed links to this paper include Oligohydramnios, Deamino Arginine Vasopressin, Pregnant People, Amniotic Fluid and Ultrasonography.

Author keywords: Desmopressin.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vasopressin and Desmopressin in 44 women.

The publication is from 2022 (Journal of medicine and life), a journal based in Romania.

More context: the Vasopressin compound page and the Desmopressin compound page, all human trials.